MC2 Therapeutics Announces Positive Phase 2a Results of Novel HSP90 Inhibitor for Hidradenitis Suppurativa Presented at EADV
The single center, Phase 2a, clinical trial conducted at Aarhus University Hospital, Denmark evaluated the efficacy and safety of MC2-32 in patients with moderate to severe (Hurley stage 2 or 3) HS.
- The single center, Phase 2a, clinical trial conducted at Aarhus University Hospital, Denmark evaluated the efficacy and safety of MC2-32 in patients with moderate to severe (Hurley stage 2 or 3) HS.
- 15 patients were recruited for the study and randomized 2:1, to 16 weeks oral treatment with 250 mg MC2-32 once daily or placebo.
- The study was a Phase 2a proof-of-concept study and not designed to obtain statistical significance.
- Joining our strong portfolio of immunology and inflammation treatments in development and on the market, MC2 Therapeutics is on its way to becoming an emerging force in the field.”